Back
BPC-157 and the 503A Bulks List: Where Prescribers Stand After the July 2026 Advisory Committee Review
Dr. Neil Panchal
Chief Medical Officer
Share:
A patient arrives with a printout, a podcast episode queued on their phone, and a specific request. They want BPC-157 for a tendon that has not settled in eight months. They have found a clinic three states away willing to prescribe it, and they would prefer to get it from you.
The clinical conversation about whether the compound is likely to help is one thing. The regulatory question sitting underneath it is separate, and it has moved twice this year. Physicians who prescribed comfortably in 2024 are now working from an outdated picture.
The status as of late July 2026
BPC-157 is not currently on the 503A Bulks List, the roster of bulk drug substances that may be used in compounding by a 503A pharmacy. It is also no longer in Category 2, the designation the FDA applies to substances flagged for significant safety concerns. That combination is unusual, and it is the source of most of the confusion in the field right now.
On 15 April 2026 the agency updated its 503A bulk drug substances document and removed BPC-157 and TB-500 from Category 2 following the withdrawal of their nominations. Removal from a category of concern reads, at first glance, like good news. It is not the same as permission. The Federal Food, Drug, and Cosmetic Act sets out three routes by which a bulk substance qualifies for use under section 503A: it is the subject of a United States Pharmacopeia or National Formulary monograph, it is a component of an FDA-approved drug, or it appears on the 503A Bulks List. BPC-157 satisfies none of the three.
The Pharmacy Compounding Advisory Committee met on 23 and 24 July 2026 to consider BPC-157 free base and BPC-157 acetate for inclusion on the list. At the time of writing the committee recommended BPC-157 move toward inclusion on the Section 503A Bulk Drug Substances List. The FDA is not bound by its votes.
How the substance arrived at this point
| Date | What happened | Effect on prescribers |
|---|---|---|
| Before 2023 | BPC-157 nominated for the 503A Bulks List and placed under evaluation | Widely compounded; many clinics treated availability as legitimacy |
| 2023 to 2025 | Assigned to Category 2, reflecting significant safety concerns | Compounding under 503A no longer defensible; several pharmacies exited |
| 15 April 2026 | Nomination withdrawn; removed from Category 2 without promotion to Category 1 | Neither prohibited by category nor permitted by listing |
| 23 to 24 July 2026 | Advisory committee reviewed free base and acetate forms for listing | PCAC recommends BPC-157 for 503A Bulks List. Outcome pending; the underlying legal analysis is unchanged until the list changes |
The pattern matters more than any single date. A compound can move out of a category of concern for procedural reasons that say nothing about its evidence base, and the practical question for a prescriber turns on the listing rather than the category.
What the categories actually govern
Category 1 substances may be used in compounding while the FDA considers them formally. Category 2 substances carry identified safety concerns and should not be compounded. Category 3 covers nominations submitted without sufficient supporting information. A substance sitting in none of these has not been cleared. It has simply left the queue.
The analysis a compounding pharmacy performs is the one that governs, and pharmacies have been notably more conservative than clinics through 2026. Several have declined to fill peptide orders that prescribers considered routine a year earlier. The reason is straightforward: enforcement risk sits with the dispenser as well as the prescriber, and the regulatory framework for compounded peptides has tightened considerably since the first wave of nominations.
The other compounds under the same review
BPC-157 has attracted the most attention, though it was reviewed alongside a group of peptides that are prescribed in similar settings and carry similar questions.
| Compound | Common clinical rationale | Regulatory position mid-2026 |
|---|---|---|
| BPC-157 | Soft tissue and gastrointestinal repair | Reviewed July 2026; not listed |
| TB-500 (thymosin beta-4 fragment) | Tissue repair, often paired with BPC-157 | Removed from Category 2 April 2026; not listed |
| Semax | Cognitive and neuroprotective claims | Under review; approved in Russia, not in the United States |
| Epitalon | Telomere and pineal signalling claims | Under review; evidence base largely non-Western |
| MOTS-c | Mitochondrial and metabolic signalling | Under review; human data limited |
For Epitalon and Semax the regulatory question sits on top of an evidence question that deserves its own examination. We have written separately about what Western medicine should do with forty years of Russian peptide research, because dismissing that literature outright is as unserious as accepting it uncritically.
Documenting the conversation, including the ones you decline
Most of the medico-legal exposure in this area comes from records that do not reflect what was actually discussed. A note reading “declined peptide request” is thin. A note that captures the patient’s specific request, the current regulatory position, the state of the human evidence, the alternatives offered, and the patient’s response is a different document entirely.
Three habits make that record hold up over time. Record the regulatory status as of a date rather than as a standing fact, since the status changes and the note does not. Separate what is unknown from what is known to be unsafe, because they call for different conversations. Note where the patient intends to source the compound if you decline, which is clinically relevant information regardless of your decision.
This is one of the reasons we built regulatory status into Longevitix as a structured field attached to the intervention rather than as free text inside a note. When a listing changes, every patient record where that compound appears can be surfaced together, rather than found one chart at a time. The same structure is what allows the platform to separate standard-of-care guidance from emerging evidence when it presents an intervention, so a clinician can see at a glance which tier they are operating in.
Keeping the record current
Regulatory pages in this area age badly, and peptide regulation has moved on a scale of months rather than years. Anything you rely on should carry a review date, and anything a patient brings you from a commercial site almost certainly does not. We update this article after each advisory committee cycle and after each revision to the 503A bulk drug substances document.
